ClinicalTrials.gov record
Uptitration Trial of Flibanserin Versus Placebo in Premenopausal Women With Hypoactive Sexual Desire Disorder
ClinicalTrials.gov ID: NCT00360555
Public ClinicalTrials.gov record NCT00360555. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Best Tolerability: 50mg Twice Daily Versus 100 mg in the Evening Versus 25 mg Twice Daily Versus Placebo in Younger Women in North America
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This trial is designed to assess the safety and efficacy of flibanserin in the treatment of premenopausal women with Hypoactive Sexual Desire Disorder (HSDD) that meets standard diagnostic criteria. Efficacy for flibanserin will be assessed vs. a parallel placebo group.
Study identification
- NCT ID
- NCT00360555
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Enrollment
- 1,584 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years to 55 Years
- Sex
- Female
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2006 (Type not available)
- Primary completion
- Mar 2008 (Actual)
- Completion
- Mar 2008 (Actual)
- Last update posted
- Jun 27, 2016
2006 – 2008
United States locations
- U.S. sites
- 64
- U.S. states
- 27
- U.S. cities
- 62
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 511.75.01015 Boehringer Ingelheim Investigational Site | Birmingham | Alabama | — | — |
| 511.75.01028 Boehringer Ingelheim Investigational Site | Mobile | Alabama | — | — |
| 511.75.01051 Boehringer Ingelheim Investigational Site | Phoenix | Arizona | — | — |
| 511.75.01063 Boehringer Ingelheim Investigational Site | Little Rock | Arkansas | — | — |
| 511.75.01017 Boehringer Ingelheim Investigational Site | Berkeley | California | — | — |
| 511.75.01014 Boehringer Ingelheim Investigational Site | Encinitas | California | — | — |
| 511.75.01042 Boehringer Ingelheim Investigational Site | Fair Oaks | California | — | — |
| 511.75.01022 Boehringer Ingelheim Investigational Site | Irvine | California | — | — |
| 511.75.01005 Boehringer Ingelheim Investigational Site | La Jolla | California | — | — |
| 511.75.01053 Boehringer Ingelheim Investigational Site | Sacremento | California | — | — |
| 511.75.01045 Boehringer Ingelheim Investigational Site | San Diego | California | — | — |
| 511.75.01065 Boehringer Ingelheim Investigational Site | Aurora | Colorado | — | — |
| 511.75.01003 Boehringer Ingelheim Investigational Site | Englewood | Colorado | — | — |
| 511.75.01030 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 511.75.01066 Boehringer Ingelheim Investigational Site | Coral Gables | Florida | — | — |
| 511.75.01040 Boehringer Ingelheim Investigational Site | Fort Meyers | Florida | — | — |
| 511.75.01001 Boehringer Ingelheim Investigational Site | Gainesville | Florida | — | — |
| 511.75.01062 Boehringer Ingelheim Investigational Site | Hollywood | Florida | — | — |
| 511.75.01032 Boehringer Ingelheim Investigational Site | Ocala | Florida | — | — |
| 511.75.01047 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 511.75.01073 Boehringer Ingelheim Investigational Site | Palm Bay | Florida | — | — |
| 511.75.01035 Boehringer Ingelheim Investigational Site | Sarasota | Florida | — | — |
| 511.75.01010 Boehringer Ingelheim Investigational Site | South Miami | Florida | — | — |
| 511.75.01041 Boehringer Ingelheim Investigational Site | St. Petersburg | Florida | — | — |
| 511.75.01033 Boehringer Ingelheim Investigational Site | Tampa | Florida | — | — |
| 511.75.01002 Boehringer Ingelheim Investigational Site | West Palm Beach | Florida | — | — |
| 511.75.01006 Boehringer Ingelheim Investigational Site | Sandy Springs | Georgia | — | — |
| 511.75.01023 Boehringer Ingelheim Investigational Site | Chicago | Illinois | — | — |
| 511.75.01031 Boehringer Ingelheim Investigational Site | Fort Wayne | Indiana | — | — |
| 511.75.01050 Boehringer Ingelheim Investigational Site | Lafayette | Louisiana | — | — |
| 511.75.01043 Boehringer Ingelheim Investigational Site | Bingham Farms | Michigan | — | — |
| 511.75.01025 Boehringer Ingelheim Investigational Site | Chaska | Minnesota | — | — |
| 511.75.01024 Boehringer Ingelheim Investigational Site | Chesterfield | Missouri | — | — |
| 511.75.01009 Boehringer Ingelheim Investigational Site | Kansas City | Missouri | — | — |
| 511.75.01060 Boehringer Ingelheim Investigational Site | Las Vegas | Nevada | — | — |
| 511.75.01004 Boehringer Ingelheim Investigational Site | New Brunswick | New Jersey | — | — |
| 511.75.01037 Boehringer Ingelheim Investigational Site | Chapel Hill | North Carolina | — | — |
| 511.75.01054 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 511.75.01069 Boehringer Ingelheim Investigational Site | Beachwood | Ohio | — | — |
| 511.75.01012 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.75.01071 Boehringer Ingelheim Investigational Site | Cincinnati | Ohio | — | — |
| 511.75.01038 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 511.75.01048 Boehringer Ingelheim Investigational Site | Cleveland | Ohio | — | — |
| 511.75.01061 Boehringer Ingelheim Investigational Site | Columbus | Ohio | — | — |
| 511.75.01020 Boehringer Ingelheim Investigational Site | Tulsa | Oklahoma | — | — |
| 511.75.01052 Boehringer Ingelheim Investigational Site | Eugene | Oregon | — | — |
| 511.75.01059 Boehringer Ingelheim Investigational Site | Medfod | Oregon | — | — |
| 511.75.01021 Boehringer Ingelheim Investigational Site | Portland | Oregon | — | — |
| 511.75.01018 Boehringer Ingelheim Investigational Site | Jenkintown | Pennsylvania | — | — |
| 511.75.01067 Boehringer Ingelheim Investigational Site | Columbia | South Carolina | — | — |
| 511.75.01070 Boehringer Ingelheim Investigational Site | Greenville | South Carolina | — | — |
| 511.75.01064 Boehringer Ingelheim Investigational Site | Knoxville | Tennessee | — | — |
| 511.75.01049 Boehringer Ingelheim Investigational Site | Nashville | Tennessee | — | — |
| 511.75.01013 Boehringer Ingelheim Investigational Site | Austin | Texas | — | — |
| 511.75.01027 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 511.75.01044 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 511.75.01011 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 511.75.01055 Boehringer Ingelheim Investigational Site | San Antonio | Texas | — | — |
| 511.75.01068 Boehringer Ingelheim Investigational Site | Waco | Texas | — | — |
| 511.75.01007 Boehringer Ingelheim Investigational Site | Charlottesville | Virginia | — | — |
| 511.75.01057 Boehringer Ingelheim Investigational Site | Norfolk | Virginia | — | — |
| 511.75.01046 Boehringer Ingelheim Investigational Site | Richmond | Virginia | — | — |
| 511.75.01019 Boehringer Ingelheim Investigational Site | Seattle | Washington | — | — |
| 511.75.01036 Boehringer Ingelheim Investigational Site | Middleton | Wisconsin | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 13 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00360555, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jun 27, 2016 · Synced Oct 26, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT00360555 live on ClinicalTrials.gov.